OntheRunPhoto/iStock via Getty Images GSK ( NYSE: GSK ) announced Thursday that it plans to distribute more than 36M doses of its influenza vaccines in the U.S. for the 2024–25 flu season.
The British drugmaker made the announcement, marking the delivery of its first vaccine shipments to U.S. healthcare providers and pharmacies in advance of the flu season.
The company has two flu vaccines, Flulaval and Fluarix, in its portfolio for this season. The egg-based vaccines are designed to target three influenza strains (two influenza A strains and one influenza B strain) in accordance with regulatory guidance. Flulaval and Fluarix will be available in a 0.
5-mL, single-dose, pre-filled syringe and are indicated for those six months or older. GSK's ( GSK ) rival Sanofi ( SNY ) announced on Wednesday that it is beginning to ship its flu vaccines for its U.S.
customers ahead of this year's vaccine season. More on GSK GSK plc: Long-Term Cash Cow GSK Breathes New Life Into Asthma Treatment With Depemokimab GSK plc (GSK) Q1 2024 Earnings Call Transcript GSK downgraded to Neutral at UBS GSk snaps six straight days of losses.
